Bajaj Finserv
|

Bajaj Finance Limited

|
Sign In
EMI Card
Notifications
Notifications
Cart
Prime
Partners
  • Fixed Deposit (IFA) Partner Fixed Deposit (IFA) Partner
  • Loan (DSA) Partner Loan (DSA) Partner
  • Debt Management Partner Debt Management Partner
  • EMI Network Partner EMI Network Partner
  • Become a Merchant Become a Merchant
  • Demat and mutual fund partner Demat and mutual fund partner
  • Partners Sign In Partners Sign In
Menu
  • Loans
    • All Loans
    • Personal Loan Apply Online Check Offer
      • Overview Flexi Personal Loan Features and Benefits Eligibility Calculator Fees and Charges How to Apply FAQs Manage your Loans Manage your Flexi Loans Contact Us
      • Loans for your Goals

        • Loan for Wedding
        • Loan for Higher Education
        • Loan for Home Renovation
        • Loan for Medical Emergency
    • Insta Personal Loan Check Offer Pre-approved Offer
      • Overview Features Eligibility Calculator Fees and Charges How to Apply Manage your Loans
      • Loans for your Goals

        • Loan for Wedding
        • Loan for Higher Education
        • Loan for Home Renovation
        • Loan for Medical Expenses
    • Business Loan Apply Online Check Offer

        Unsecured

      • MSME World Overview Features EMI Calculator Eligibility How to Apply Fees & Charges Manage your Loans Manage your Flexi Loans
      • Secured

      • Overview Features EMI Calculator Eligibility How to Apply Fees & Charges Manage your Loans Manage your Flexi Loans
      • Types of Business Loans

      • Business Loan for Chartered Accountants Loan Against Property for Chartered Accountant Personal Loan for Chartered Accountants
    • Gold Loan Apply Online

        New Loan

      • Overview Features EMI Calculator Eligibility How to Apply Manage your Gold Loan Interest Rate and Charges Gold Rate
      • Balance Transfer

      • Overview Features EMI Calculator Eligibility How to Apply Interest Rate and Charges
    • Loans for Doctors Apply Online Check Offer

        UNSECURED

      • Doctor World Overview Features Eligibility How to Apply Fees & Charges Manage your Loans Manage your Flexi Loans
      • SECURED

      • Overview EMI Calculator Features Eligibility How to Apply Fees and charges Manage your loan
      • Types of Doctor Loans

      • Business Loan for Doctors Personal Loan For Doctors Loan Against Property for Doctors Indemnity Insurance Medical Practice Loan
    • Medical Equipment Finance Apply Online
      • Overview Features Eligibility How to Apply Fees & Charges
    • Loans for CAs Apply Online Check Offer

        UNSECURED

      • Overview Features Eligibility How to Apply Fees & Charges Manage your Loans Manage your Flexi Loans
      • SECURED

      • Overview EMI Calculator Features Eligibility How to Apply Fees and charges Manage your loan
      • Types of CA Loans

      • Business Loan for Chartered Accountants Loan Against Property for Chartered Accountants Personal Loan for Chartered Accountants
    • Commercial Lending
      • Overview Term Loans Working Capital Products Corporate Lease Rental Discounting
    • Home Loan Apply Online Check Offer

        Home Loan

      • Home Loan World Overview Features EMI Calculator Eligibility How to Apply Fees and Charges Home Loan Interest Rate
      • Balance Transfer

      • Overview Features Eligibility How to Apply Fees and Charges
      • Categories

      • Home Loan for Doctors Home Loan for Self-employed Home Loan for Salaried
      • Categories

      • Home Loan Balance Transfer for Doctors Home Loan Balance Transfer for Self-employed Home Loan Balance Transfer for Salaried
    • Loan Against Property Apply Online

        LOAN AGAINST PROPERTY

      • Overview Features EMI Calculator Eligibility How to Apply Fees & Charges Loan Against Property Interest Rate
      • BALANCE TRANSFER

      • Overview Features Eligibility How to Apply Fees & Charges
    • Lease Rental Discounting
    • Loan Against Securities Apply Online

        LOAN AGAINST SHARES

      • Overview Features Eligibility How to Apply Fees & Charges Manage your Loan Against Securities FAQ
      • Loan Against Mutual Funds

      • Overview Features Eligibility How to Apply Fees & Charges FAQ
      • Loan Against Bonds

      • Overview Features and Benefits Eligibility How to Apply Fees and Charges FAQs
      • Loan Against Insurance Policy

      • Overview Features and Benefits Eligibility How to Apply Fees and Charges FAQs
      • ESOP Financing

      • Overview Features and Benefits Eligibility How to Apply Fees and Charges FAQs
    • Two-wheeler Loan Apply Online Check Offer
      • Overview Eligibility Features Interest Rates How to Apply Manage your Two-wheeler Loan FAQs
    • New Car Finance Apply Now Check Offer
      • Auto World Overview Features Eligibility How to Apply Interest Rates and Charges FAQs Manage your loan Manage your flexi loan
    • Used Car Loan Apply Now Check Offer

        Used Car Finance

      • Auto World Explore Used Cars and Loan Overview Features and benefits Eligibility EMI Calculator Used Car Loan Eligibility Calculator Fees and charges How to Apply FAQs Manage your loan Manage your flexi loan
      • Categories

      • Loan against car Car loan balance transfer
    • Loan Against Car Apply Now Check Offer

        Loan Against Car

      • Auto World Overview Features and benefits Eligibility EMI Calculator Loan Against Car Eligibility Calculator Fees and charges How to Apply FAQS Manage your loan Manage your flexi loan
      • Categories

      • Used car loan Car loan balance transfer
    • Car Loan Balance Transfer and Top-up Apply Now Check Offer

        Balance Transfer

      • Auto World Overview Features and benefits Eligibility EMI Calculator Car Loan Balance Transfer and Top Up Eligibility Calculator Fees and Charges How to Apply Manage your loan FAQS Manage your flexi loan
      • Categories

      • Used car loan Loan against car
    • Microfinance Group Loan
    • Tractor Loan
    • Loan for Lawyer
    • Easy EMI Loan
  • All on EMI
    • Electronics
    • Two-wheelers
    • Lifestyle
    • Travel
      • Our Partner Make My Trip Goibibo IRCTC
    • Shop on Ecommerce
      • Our Partner Flipkart Amazon
    • Offers & Promotions
    • Tractor
  • Bajaj Mall
    • Smartphones
    • Washing Machines
    • LED TVs
    • Refrigerators
    • Air Conditioners
    • Water Purifiers
    • Two-wheelers
    • Smartwatches
    • Laptops
    • Mattresses
    • Furniture
    • Kitchen Appliances
    • Cycles
    • Fitness Equipment
    • Air Cooler
    • Watches
    • Audio Devices
    • Camera Accessories
  • Card
    • Insta EMI Card Apply Online
      • Overview Features and Benefits Eligibility Fees and Charges How to Apply Manage your Insta EMI Card Contact Us
  • Investments
    • All Investments
    • Fixed Deposit Open FD
      • Overview FD Calculator Features and Benefits FD Interest Rates Eligibility and Documents How to Invest FAQs Manage your FD Contact Us
      • FIXED DEPOSIT FOR YOUR GOALS

        • Fixed Deposit for Retirement Fund
        • Fixed Deposit for Higher Education
        • Fixed Deposit for Home Expenses
        • Fixed Deposit for Wedding Expenses
    • Mutual Funds Open MF Account Explore Funds

        About the Product

      • SIP Calculator Overview Explore All MFs How to Invest FAQs Contact Us
      • Fund Category

      • Debt Funds Equity Funds Hybrid Funds ELSS Funds Thematic Funds Multi Cap Fund NFO Large Cap Mutual Funds Mid Cap Mutual Funds Small Cap Mutual Funds Liquid Mutual Funds Aggressive Hybrid Mutual Funds
      • Funds by Returns

      • 1 Month Returns 3 Months Returns 1 Year Returns 3 Years Returns Max Returns
      • Quick Links

      • Portfolio Order in progress Open mutual fund account Dashboard New Fund Offer (NFO)
    • Stock Trading Open A/C
      • Start Trading Open Demat Account Overview FAQ Contact Us
    • Partner Portal
    • Become Our Partner
  • Insurance
    • Insurance Mall
    • Health Insurance Explore Plans

        Health Insurance

      • Overview Get Quote FAQs
      • Family Health Insurance

      • Aditya Birla Group Activ Health Plan (ABCD) Bajaj Allianz Health Guard Insurance Plan ManipalCigna Pro-Health Group Niva Bupa Health Plus Plan Aditya Birla Active Assure Diamond
      • Top-up Health Insurance

      • Group Activ Health Super Top-Up Bajaj Allianz Extra care plus plan
      • Partners

      • Aditya Birla Health Insurance Bajaj Allianz General Insurance Niva Bupa Health Insurance Bajaj Finserv Health ManipalCigna Health Insurance
    • Car Insurance Explore Plans

        Car Insurance

      • Overview Get Quote FAQs
      • Partners

      • ACKO General Insurance Bajaj Allianz General Insurance SBI General Insurance
      • Comprehensive Car Insurance

      • ACKO Car Insurance Bajaj Allianz Car Insurance SBI General Car Insurance
      • Own Damage

      • Bajaj Allianz Car Insurance SBI General Car Insurance
    • Pocket Insurance Explore Plans

        Best Seller

      • Personal Accident Cover Group Activ Health Super top up Cover
      • Under 699

      • Cancer Secure Gym Injury Insurance Pregnancy Complications Cover Baggage Insurance
      • Health Must Have

      • Niva Bupa Health Plus Dental Cover Sports/Fitness Injury Fracture Cover Health Plus Hospital Cash
      • Monsoon Insurance

      • Dengue & Malaria Cover Monsoon Insurance Viral Fever(Infection) CPP Liv Protect Group Activ Secure Policy- Personal Accident Cover 18-55 Years
    • Investment Plans Explore Plans

        Investment Plans

      • Overview
      • Partners

      • HDFC Life Bajaj Allianz Life Insurance
      • Guaranteed Savings

      • HDFC Life Guaranteed Savings Plan Bajaj Allianz Life POS Goal Suraksha Plan
    • Life Insurance Explore Plans

        Life Insurance

      • Overview Get Quote
      • Partner

      • Bajaj Allianz Life Insurance HDFC Life insurance Future Generali India Life Insurance
    • Professional Indemnity Explore Now

        Professional Indemnity

      • Overview Get Quote Bajaj Allianz Professional Indemnity Insurance Plan View All
      • Partners

      • Bajaj Allianz General Insurance
    • Manage your Insurance
  • Payments
    • All Payments
    • Mobile Recharge Pay Now
      • Jio Airtel Vi BSNL
    • Electricity Bill Payment Pay Now
      • Maharashtra State Electricity Distbn Co Ltd West Bengal Electricity Torrent Power Tamil Nadu Electricity Board (TNEB) Central Power Distribution Corporation Ltd. of Andhra Pradesh (APCPDCL) Calcutta Electric Supply Corporation (CESC) Jaipur Vidyut Vitran Nigam (JVVNL) APEPDCL-Eastern Power Distribution CO AP Ltd South Bihar Power Distribution Company Ltd. Southern Power Distribution Co Ltd of Andhra Pradesh Purvanchal Vidyut Vitaran Nigam Limited
    • Gas Booking Pay Now
      • Indane Gas (Indian Oil) Bharat Gas (BPCL) HP Gas (HPCL)
    • Loan Repayment Pay Now
      • Bajaj Finance Limited Agent Collection DMI Finance Private Limited Annapurna Finance Private Limited-MFI Bajaj Auto Finance Ujjivan Small Finance Bank TVS Credit IIFL Finance Limited
    • FASTag Buy New Recharge
      • IDFC FIRST Bank - FASTag Airtel Payments Bank NETC FASTag ICICI Bank FASTag HDFC  Bank - FASTag State Bank of India - NETC FASTag Kotak Mahindra Bank - FASTag Axis Bank FASTag IndusInd Bank FASTag
    • DTH Pay Now
      • Dish TV Videocon D2H Airtel DTH Tata Sky Sun Direct TV
    • Credit Card Bill payment Pay Now
      • SBI Card RBL Bank Credit Card HDFC Bank Credit Card ICICI Bank Credit Card Axis Bank Credit Card DBS Credit Card BoB Credit Card IDFC FIRST Bank Credit Card Yes Bank Credit Card Kotak Mahindra Bank Credit Card AU Bank Credit Card
    • Bajaj Pay Wallet
    • Bajaj Pay Gift Card Buy Now
      • My Cards Gift Card Categories
    • Rewards
      • Rewards & Offers Flipkart Gift Card Redbus Gift Card Swiggy Gift Card Amazon Gift Card Zomato Gift Card
  • Offers
    • All Offers
    • Loans
    • Electronics and Appliances
    • Personal Loan
    • EMI Card
    • Investment
    • Business Loan
    • Lifestyle
    • Home Loan
    • Insurance
    • Doctor Loan
    • Two wheeler
    • CA Loan
    • Used Cars
    • Loan Against Securities
    • Broking
    • Rewards
    • Gold Loan
    • Payments
  • Services
    • Locate Us
      • Branches EMI Network Partner Stores Hospitals & Wellness Centres Insurance Network Hospitals Collection Centres
    • All Service Guides
    • Raise a Request
      • Overview Raise a Request Follow-up on an open request Re-open a closed request
    • Manage your Profile
      • Overview Contact Details Personal Details GST Details
    • Manage your Mandate
      • Overview Register Mandate Change Mandate
    • Repay your Loans
      • Overview Clear Overdue EMIs Pay Advance EMIs Part-prepay your Loans Foreclose your Loans Manage your loan settlement
    • Manage your Loans
      • Overview Consumer Durable Loans Flexi Loans Loan Against Fixed Deposit Loan Against Securities Gold Loan Two-wheeler Loan
    • Manage your Cards
      • Insta EMI card Health EMI Network Card
    • Manage your Investments
      • Fixed Deposit Systematic Deposit Plan
    • Manage your Insurance
      • Overview Policy Details Renew your Policy Claim your Policy Cancel your Policy Surrender your Policy
  • About Bajaj Finserv
    • Investor Relations
    • People and Committees
    • About Us
    • Impact
    • TICC
    • Careers
  • pay emi image Pay EMI
  • Do not call image Do not call
  • Download the app image Download the app
Sign In

Main Menu

  • Food & Grocery
    Main Menu
    Food & Grocery
    • Food & Beverages
    • Grocery
    • Fashion
    • Beauty & Personal Care
    • Health & Wellness
    • Home & Kitchen
  • Bajaj Pay
    Main Menu
    Bajaj Pay
    • Bajaj Pay
    • Wallet
    • Refer & Earn
    • Mobile Recharge
    • Buy FASTag
    • Bill Payments & Other Recharges
    • Add Money
  • Loans
    Main Menu
    Loans
    • Personal Loan
    • Gold Loan
    • Business Loan
    • Loan for Doctors
    • Home Loan
    • Secured Business Loan
    • Loan Against Property
    • Loan Against Shares
    • Loan for Chartered Accountants
    • Medical Equipment Finance
    • Loan Against Property Balance Transfer
    • Home Loan Balance Transfer
    • Loan Against Mutual Funds
    • Loan Against Bonds
    • Loan Against Insurance Policy
    • ESOP Financing
    • Two-wheeler Loan
    • Buy a Used Car
    • Tractor Loan
    • Used Car Loan
    • Loan Against Car
    • Car Loan Balance Transfer and Top-up
    • New Car Loan
    • Loan for Lawyer
    • Industrial Equipment Finance
    • Industrial Equipment Balance Transfer
    • Industrial Equipment Refinance
    • Easy EMI Loan
  • Electronics & Smartphones
    Main Menu
    Electronics & Smartphones
    • Smartphones
    • Air Conditioner
    • Led TVs
    • Air Coolers
    • Refrigerators
    • Washing Machines
    • Laptops
    • Easy EMI Loan
  • EMI Card
    Main Menu
    EMI Card
    • Insta EMI Card
  • Share Market
    Main Menu
    Share Market
    • Trading Account
    • Open Demat Account
    • Margin Trading Financing
    • Share Market
    • Invest in IPO
    • All stocks
    • Top gainers
    • Top losers
    • 52 week high
    • 52 week low
    • Loan against shares
  • MSME World
    Main Menu
    MSME World
    • Business Loan
    • Secured Business Loan
    • Loan against property
    • Loans against property balance transfer
    • Loan against shares
    • Home Loan
    • Loans against mutual funds
    • Loan against bonds
    • Loan against insurance policy
    • Industrial Equipment Finance
    • Industrial Equipment Balance Transfer
    • Industrial Equipment Refinance
  • Insurance
    Main Menu
    Insurance
    • Health Insurance
    • Term Life Insurance
    • ULIP Plan
    • Savings Plan
    • Retirement Plans
    • Child Plans
    • Investment Plans
    • Wallet Care
    • Waller Care Entertainment +
    • Personal Accident Care
    • EMI/SIP Cover
    • Health Prime Max
    • Fonesafe Lite
    • Mobile Protect
    • Wallet Protekt
    • Dengue Cover
    • Niva Bupa Health Plus
    • Health Plus Hospital Cash
    • Four Wheeler Insurance
  • Bajaj Prime
    Main Menu
    Bajaj Prime
    • Get Bajaj Prime
  • Investments
    Main Menu
    Investments
    • Fixed Deposit
    • Renew Fixed Deposit
    • ULIP Plan
    • Savings Plan
    • Retirement Plans
    • Child Plans
    • Free Demat Account
    • Invest in Stocks
    • Invest in IPO
    • Margin Trading Facility
    • Equity Mutual Funds
    • Debt Mutual Funds
    • Hybrid Mutual Funds
    • New Fund Offers
    • Open Mutual Fund Account
  • Gold Loan
    Main Menu
    Gold Loan
    • Apply for Gold Loan
    • Transfer your Gold Loan with Us
  • Two Wheeler World
    Main Menu
    Two Wheeler World
    • Bike
    • Scooter
    • Electric Vehicle
    • Best Sellers
    • Popular Brands
  • Credit Score
    Main Menu
    Credit Score
    • Check your Credit Score
  • Fun Zone
    Main Menu
    Fun Zone
    • Engagement Zone
    • Game Zone
  • Auto World
    Main Menu
    Auto World
    • New Car Loan
    • Used Car Loan
    • Loan Against Car
    • Car Loan Balance Transfer and Top-up
    • Buy a Used Car
  • Easy EMI Loan
    Main Menu
    Easy EMI Loan
    • Mobiles and Electronics on Easy EMI
  • Calculators
    Main Menu
    Calculators
    • Personal Loan EMI Calculator
    • Personal Loan Eligibility Calculator
    • Home Loan EMI Calculator
    • Home Loan Eligibility Calculator
    • Good & Service Tax (GST) Calculator
    • Flexi Day Wise Interest Calculator
    • Flexi Transaction Calculator
    • Secured Business Loan Eligibility Calculator
    • Fixed Deposits Interest Calculator
    • Two wheeler Loan EMI Calculator
    • New Car Loan EMI Calculator
    • Used Car Loan EMI Calculator
    • All Calculator
  • Lifestyle
    Main Menu
    Lifestyle
    • Hot Deals
    • Clearance Sale
    • Kitchen Appliances
    • Tyres
    • Camera & Accessories
    • Mattresses
    • Furniture
    • Watches
    • Music & Audio
    • Cycles
    • Mixer & Grinder
    • Luggage & Travel
    • Fitness Equipment
    • Fans
  • Doctor World
    Main Menu
    Doctor World
    • Personal Loan for Doctors
    • Business loan for Doctors
    • Medical Equipment Finance
    • Secured Business Loan
    • Loan against property
    • Loan against share
    • Gold Loan
    • Home Loan
  • All on EMI
    Main Menu
    All on EMI
    • Smartphones
    • Air Conditioners
    • LED TVs
    • Air Coolers
    • Refrigerators
    • Washing Machines
    • Laptops
    • Water Purifiers
    • Tablets
    • Kitchen Appliances
    • Mattresses
    • Furniture
    • Music and Audio
    • Cameras & Accessories
    • Cycle
    • Watches
    • Tyres
    • Luggage & Travel
    • Fitness Equipment
    • Tractor
    • Easy EMI Loan
  • Home Loan World
    Main Menu
    Home Loan World
    • Home Loan
    • Transfer your existing Home loan
    • Loan against Property
    • Home Loan for Salaried
    • Home loan for self employed
    • Home Loan EMI Calculator
    • Home Loan eligibility calculator
    • Home Loan balance transfer
  • Deals and Savings
    Main Menu
    Deals and Savings
    • Easy EMI
    • Offer World
    • 1 EMI OFF
    • New Launches
    • Zero Down Payment
    • Clearance Sale
    • Bajaj Mall Sale
  • Articles
    Main Menu
    Articles
    • Articles
  • Loan Payments
    Main Menu
    Loan Payments
    • Overdue Payments
    • Other Payments
  • Bank details/ Documents
    Main Menu
    Bank details/ Documents
    • Document Center
    • Bank details & Documents
    • Tax Invoice Certificate
  • Do Not Call Service
    Main Menu
    Do Not Call Service
    • Do Not Call Service
  • Your Things
    Main Menu
    Your Things
    • Your Orders
    • Hamara Mall Orders
  • Rewards
    Main Menu
    Rewards
    • Explore Bajaj Prime
    • Explore Rewards
    • Buy Deals & Gift cards
  • Partners
    Main Menu
    Partners
    • Fixed Deposit (IFA) Partner
    • Loan (DSA) Partner
    • Debt Management Partner
    • EMI Network Partner
    • Become a Merchant
    • Partner Sign-in
  • What's New
    Main Menu
    What's New
    • Food & Shopping
    • Credit Card Hub
    • ULIP Plans
    • Top Gainers Stock
    • Top Losers Stock
    • Saving Plan
    • Term Insurance
    • Easy EMI Loan
  • Watch Live
    Main Menu
    Watch Live
    • Live Videos
  • Help and Support
  • Settings
    Main Menu
    Settings
    • Update Profile
    • Manage Consent
    • Refer and Earn
    • About Us
    • Important Information
    • Terms of Service
    • Privacy Policy
    • Fair Practice Code
    • Citizen Charter
    • LogOut
    • TICC
  • Home
  • Account
  • More
  • Pay EMIs
  • Menu
Menu
Food & Grocery

Food & Grocery

  • Food & BeveragesFood & Beverages
  • GroceryGrocery
  • FashionFashion
  • Beauty & Personal CareBeauty & Personal Care
  • Health & WellnessHealth & Wellness
  • Home & KitchenHome & Kitchen
Bajaj Pay

Bajaj Pay

  • Bajaj PayBajaj Pay
  • WalletWallet
  • Refer & EarnRefer & Earn
  • Mobile RechargeMobile Recharge
  • Buy FASTagBuy FASTag
  • Bill Payments & Other RechargesBill Payments & Other Recharges
  • Add MoneyAdd Money
Loans

Loans

  • Personal LoanPersonal Loan
  • Gold LoanGold Loan
  • Business LoanBusiness Loan
  • Loan for DoctorsLoan for Doctors
  • Home LoanHome Loan
  • Secured Business LoanSecured Business Loan
  • Loan Against PropertyLoan Against Property
  • Loan Against SharesLoan Against Shares
  • Loan for Chartered AccountantsLoan for Chartered Accountants
  • Medical Equipment FinanceMedical Equipment Finance
  • Loan Against Property Balance TransferLoan Against Property Balance Transfer
  • Home Loan Balance TransferHome Loan Balance Transfer
  • Loan Against Mutual FundsLoan Against Mutual Funds
  • Loan Against BondsLoan Against Bonds
  • Loan Against Insurance PolicyLoan Against Insurance Policy
  • ESOP FinancingESOP Financing
  • Two-wheeler LoanTwo-wheeler Loan
  • Buy a Used CarBuy a Used Car
  • Tractor LoanTractor Loan
  • Used Car LoanUsed Car Loan
  • Loan Against CarLoan Against Car
  • Car Loan Balance Transfer and Top-upCar Loan Balance Transfer and Top-up
  • New Car LoanNew Car Loan
  • Loan for LawyerLoan for Lawyer
  • Industrial Equipment FinanceIndustrial Equipment Finance
  • Industrial Equipment Balance TransferIndustrial Equipment Balance Transfer
  • Industrial Equipment RefinanceIndustrial Equipment Refinance
  • Easy EMI LoanEasy EMI Loan
Electronics & Smartphones

Electronics & Smartphones

  • SmartphonesSmartphones
  • Air ConditionerAir Conditioner
  • Led TVsLed TVs
  • Air CoolersAir Coolers
  • RefrigeratorsRefrigerators
  • Washing MachinesWashing Machines
  • LaptopsLaptops
  • Easy EMI LoanEasy EMI Loan
EMI Card

EMI Card

  • Insta EMI CardInsta EMI Card
Share Market

Share Market

  • Trading AccountTrading Account
  • Open Demat AccountOpen Demat Account
  • Margin Trading FinancingMargin Trading Financing
  • Share MarketShare Market
  • Invest in IPOInvest in IPO
  • All stocksAll stocks
  • Top gainersTop gainers
  • Top losersTop losers
  • 52 week high52 week high
  • 52 week low52 week low
  • Loan against sharesLoan against shares
msme-world

MSME World

  • Business LoanBusiness Loan
  • Secured Business LoanSecured Business Loan
  • Loan against propertyLoan against property
  • Loans against property balance transferLoans against property balance transfer
  • Loan against sharesLoan against shares
  • Home LoanHome Loan
  • Loans against mutual fundsLoans against mutual funds
  • Loan against bondsLoan against bonds
  • Loan against insurance policyLoan against insurance policy
  • Industrial Equipment FinanceIndustrial Equipment Finance
  • Industrial Equipment Balance TransferIndustrial Equipment Balance Transfer
  • Industrial Equipment RefinanceIndustrial Equipment Refinance
Insurance

Insurance

  • Health InsuranceHealth Insurance
  • Term Life InsuranceTerm Life Insurance
  • ULIP PlanULIP Plan
  • Savings PlanSavings Plan
  • Retirement PlansRetirement Plans
  • Child PlansChild Plans
  • Investment PlansInvestment Plans
  • Wallet CareWallet Care
  • Waller Care Entertainment +Waller Care Entertainment +
  • Personal Accident CarePersonal Accident Care
  • EMI/SIP CoverEMI/SIP Cover
  • Health Prime MaxHealth Prime Max
  • Fonesafe LiteFonesafe Lite
  • Mobile ProtectMobile Protect
  • Wallet ProtektWallet Protekt
  • Dengue CoverDengue Cover
  • Niva Bupa Health PlusNiva Bupa Health Plus
  • Health Plus Hospital CashHealth Plus Hospital Cash
  • Four Wheeler InsuranceFour Wheeler Insurance
Bajaj Prime

Bajaj Prime

  • Get Bajaj PrimeGet Bajaj Prime
Investments

Investments

  • Fixed DepositFixed Deposit
  • Renew Fixed DepositRenew Fixed Deposit
  • ULIP PlanULIP Plan
  • Savings PlanSavings Plan
  • Retirement PlansRetirement Plans
  • Child PlansChild Plans
  • Free Demat AccountFree Demat Account
  • Invest in StocksInvest in Stocks
  • Invest in IPOInvest in IPO
  • Margin Trading FacilityMargin Trading Facility
  • Equity Mutual FundsEquity Mutual Funds
  • Debt Mutual FundsDebt Mutual Funds
  • Hybrid Mutual FundsHybrid Mutual Funds
  • New Fund OffersNew Fund Offers
  • Open Mutual Fund AccountOpen Mutual Fund Account
Gold Loan

Gold Loan

  • Apply for Gold LoanApply for Gold Loan
  • Transfer your Gold Loan with UsTransfer your Gold Loan with Us
Two Wheeler World

Two Wheeler World

  • BikeBike
  • ScooterScooter
  • Electric VehicleElectric Vehicle
  • Best SellersBest Sellers
  • Popular BrandsPopular Brands
Credit Score

Credit Score

  • Check your Credit ScoreCheck your Credit Score
Fun Zone

Fun Zone

  • Engagement ZoneEngagement Zone
  • Game ZoneGame Zone
Auto World

Auto World

  • New Car LoanNew Car Loan
  • Used Car LoanUsed Car Loan
  • Loan Against CarLoan Against Car
  • Car Loan Balance Transfer and Top-upCar Loan Balance Transfer and Top-up
  • Buy a Used CarBuy a Used Car
Easy EMI Loan

Easy EMI Loan

  • Mobiles and Electronics on Easy EMIMobiles and Electronics on Easy EMI
Calculators

Calculators

  • Personal Loan EMI CalculatorPersonal Loan EMI Calculator
  • Personal Loan Eligibility CalculatorPersonal Loan Eligibility Calculator
  • Home Loan EMI CalculatorHome Loan EMI Calculator
  • Home Loan Eligibility CalculatorHome Loan Eligibility Calculator
  • Good & Service Tax (GST) CalculatorGood & Service Tax (GST) Calculator
  • Flexi Day Wise Interest CalculatorFlexi Day Wise Interest Calculator
  • Flexi Transaction CalculatorFlexi Transaction Calculator
  • Secured Business Loan Eligibility CalculatorSecured Business Loan Eligibility Calculator
  • Fixed Deposits Interest CalculatorFixed Deposits Interest Calculator
  • Two wheeler Loan EMI CalculatorTwo wheeler Loan EMI Calculator
  • New Car Loan EMI CalculatorNew Car Loan EMI Calculator
  • Used Car Loan EMI CalculatorUsed Car Loan EMI Calculator
  • All CalculatorAll Calculator
Lifestyle

Lifestyle

  • Hot DealsHot Deals
  • Clearance SaleClearance Sale
  • Kitchen AppliancesKitchen Appliances
  • TyresTyres
  • Camera & AccessoriesCamera & Accessories
  • MattressesMattresses
  • FurnitureFurniture
  • WatchesWatches
  • Music & AudioMusic & Audio
  • CyclesCycles
  • Mixer & GrinderMixer & Grinder
  • Luggage & TravelLuggage & Travel
  • Fitness EquipmentFitness Equipment
  • FansFans
Doctor World

Doctor World

  • Personal Loan for DoctorsPersonal Loan for Doctors
  • Business loan for DoctorsBusiness loan for Doctors
  • Medical Equipment FinanceMedical Equipment Finance
  • Secured Business LoanSecured Business Loan
  • Loan against propertyLoan against property
  • Loan against shareLoan against share
  • Gold LoanGold Loan
  • Home LoanHome Loan
All on EMI

All on EMI

  • SmartphonesSmartphones
  • Air ConditionersAir Conditioners
  • LED TVsLED TVs
  • Air CoolersAir Coolers
  • RefrigeratorsRefrigerators
  • Washing MachinesWashing Machines
  • LaptopsLaptops
  • Water PurifiersWater Purifiers
  • TabletsTablets
  • Kitchen AppliancesKitchen Appliances
  • MattressesMattresses
  • FurnitureFurniture
  • Music and AudioMusic and Audio
  • Cameras & AccessoriesCameras & Accessories
  • CycleCycle
  • WatchesWatches
  • TyresTyres
  • Luggage & TravelLuggage & Travel
  • Fitness EquipmentFitness Equipment
  • TractorTractor
  • Easy EMI LoanEasy EMI Loan
Home Loan World

Home Loan World

  • Home LoanHome Loan
  • Transfer your existing Home loanTransfer your existing Home loan
  • Loan against PropertyLoan against Property
  • Home Loan for SalariedHome Loan for Salaried
  • Home loan for self employedHome loan for self employed
  • Home Loan EMI CalculatorHome Loan EMI Calculator
  • Home Loan eligibility calculatorHome Loan eligibility calculator
  • Home Loan balance transferHome Loan balance transfer
Deals and Savings

Deals and Savings

  •  Easy EMI Easy EMI
  • Offer WorldOffer World
  • 1 EMI OFF1 EMI OFF
  • New LaunchesNew Launches
  • Zero Down PaymentZero Down Payment
  • Clearance SaleClearance Sale
  • Bajaj Mall SaleBajaj Mall Sale
Articles

Articles

  • ArticlesArticles
Loan Payments

Loan Payments

  • Overdue PaymentsOverdue Payments
  • Other PaymentsOther Payments
Bank details/ Documents

Bank details/ Documents

  • Document CenterDocument Center
  • Bank details & DocumentsBank details & Documents
  • Tax Invoice CertificateTax Invoice Certificate
Do Not Call Service

Do Not Call Service

  • Do Not Call ServiceDo Not Call Service
Your Things

Your Things

  • Your OrdersYour Orders
  • Hamara Mall OrdersHamara Mall Orders
Rewards

Rewards

  • Explore Bajaj PrimeExplore Bajaj Prime
  • Explore RewardsExplore Rewards
  • Buy Deals & Gift cardsBuy Deals & Gift cards
Partners

Partners

  • Fixed Deposit (IFA) PartnerFixed Deposit (IFA) Partner
  • Loan (DSA) PartnerLoan (DSA) Partner
  • Debt Management PartnerDebt Management Partner
  • EMI Network PartnerEMI Network Partner
  • Become a MerchantBecome a Merchant
  • Partner Sign-inPartner Sign-in
What's New

What's New

  •  Food & Shopping Food & Shopping
  • Credit Card HubCredit Card Hub
  • ULIP PlansULIP Plans
  • Top Gainers StockTop Gainers Stock
  • Top Losers StockTop Losers Stock
  • Saving PlanSaving Plan
  • Term InsuranceTerm Insurance
  • Easy EMI LoanEasy EMI Loan
Watch Live

Watch Live

  • Live VideosLive Videos
Help and Support
Settings
Update Profile Manage Consent Refer and Earn About Us Important Information Terms of Service Privacy Policy Fair Practice Code Citizen Charter LogOut TICC
Relations Documents Profile Loan Payments

Error

400

We are sorry.

There's nothing here yet.

BACK TO HOMEPAGE
  • Overview
  • Performance
  • Fundamentals
  • Financials
  • Technical summary
  • Shareholding pattern
  • About
  • View more stocks
  • All stocks
  • Top gainers
  • Top losers
  • FAQs

SUN PHARMACEUTICAL IND L

SUNPHARMA

NSE

BSE

Pharmaceuticals

₹ 1720.9

-10.9 -0.62%

OPEN DEMAT ACCOUNT

Stock price as on May 22 2025 10:47 AM

Stock performance

Performance

Company fundamentals

Fundamentals

Company financials

Financials

Stock technical summary

Technical summary

Company shareholding pattern

Shareholding pattern

About

About {Company_Name}

Similar stocks

Similar stocks

FAQs

FAQs

Performance Graph
YTD 1 Week 1 Months 3 Months 6 Months 1 Year -0.62% 0.45% -2.12% 2.3% -4.05% 10.82%

Sun Pharmaceutical IndL stock performance

Today’s low

1709.0

Today’s high

1740.0

1720.9

52 week low

1377.2

52 week high

1960.35

1714.2

Open

1734.2

Previous close

1731.8

Share volume

342064.0

Total traded value (Lakh)

5863.66

Upper circuit

1904.9

Lower circuit

1558.7

Stock performance

This data indicates the stock's performance over a specific period, measured by tracking its price movements.

<p><b>Open</b></p> <p style="text-align: left;">The price at which a stock begins trading at the start of the trading day.<br /> </p> <p> </p> <p><b>Previous close</b></p> <p style="text-align: left;">The price at which a stock ended trading on the previous day.<br /> </p> <p> </p> <p><b>Share volume</b></p> <p style="text-align: left;">The total number of shares  traded during a specific period, typically within a trading day.</p> <p> </p> <p><b>Trade value</b></p> <p>The total value of all trades made during a specific period.<br /> </p> <p> </p> <p><b>Upper circuit</b></p> <p>The maximum allowed price increase in a stock during a single session, after which trading is temporarily paused.</p> <p> </p> <p><b>Lower circuit</b></p> <p>The maximum allowed price decrease in a stock during a single session, after which trading is temporarily paused.</p> <p> </p>

Sun Pharmaceutical IndL fundamentals

Market cap (Cr)
415516.8
P/E ratio (TTM)
130.03
Book value per share
₹ 0.0
Beta
0.52
Return on equity
12.05
Earnings per share (TTM)
₹ 13.13
Dividend yield
0.79%
Net profit/quarter (Cr)
₹ 1181.05

Fundamentals

Understand the common terms associated with a company's stock fundamentals

<p><b>Market cap</b></p> <p>The total value of a company's outstanding shares, calculated by multiplying the current stock price with the number of shares.<br> </p> <p>&nbsp;</p> <p><b>P/E ratio (TTM)</b></p> <p style="text-align: left;">The price-to-earnings ratio, showing how investors value a company by dividing the stock price by earnings per share (EPS).<br> </p> <p>&nbsp;</p> <p><b>Book value per share</b></p> <p style="text-align: left;">The value of a company per share, calculated by dividing the company's net assets by the total number of shares.</p> <p style="text-align: left;">&nbsp;</p> <p><b>Beta</b></p> <p>A measure of a stock’s volatility compared to the&nbsp; market:</p> <p>&nbsp;</p> <p>Beta of 1: Stock moves with the market.</p> <p>Beta &gt; 1: More volatile.</p> <p>Beta &lt; 1: Less volatile.</p> <p>&nbsp;</p> <p><b>Return on equity</b></p> <p style="text-align: left;">Indicates how profitable a company is compared to shareholder investment, calculated by dividing net income by shareholders' equity.<br> </p> <p>&nbsp;</p> <p><b>Earnings per share (TTM)</b></p> <p>The profit earned per share over the past 12 months.<br> </p> <p>&nbsp;</p> <p><b>Dividend yield</b></p> <p>The return on investment from dividends, calculated by dividing the annual dividend by the current share price.</p> <p>&nbsp;</p> <p><b>Net profit/quarter</b></p> <p>The profit a company makes in a quarter after all expenses and taxes are deducted.</p> <p>&nbsp;</p>

Sun Pharmaceutical IndL financials

(Values in Cr)

Revenue

Net income

Revenue

Particulars

202412 (₹ value in crores)

Revenue

5985.33

Operating expense

4995.27

Net income

1181.05

Net profit margin

19.73%

Earnings per share

4.9

EBITDA

1771.86

Effective tax rate

6.63
Revenue

Particulars

202409 (₹ value in crores)

Revenue

5123.67

Operating expense

4318.37

Net income

863.29

Net profit margin

16.84%

Earnings per share

3.6

EBITDA

1424.91

Effective tax rate

3.61
Revenue

Particulars

202406 (₹ value in crores)

Revenue

4409.74

Operating expense

4322.89

Net income

237.82

Net profit margin

5.39%

Earnings per share

1.0

EBITDA

843.81

Effective tax rate

7.79
Revenue

Particulars

202403 (₹ value in crores)

Revenue

5536.99

Operating expense

4356.24

Net income

867.6

Net profit margin

15.66%

Earnings per share

3.6

EBITDA

2012.4

Effective tax rate

38.1
Revenue

Particulars

202312 (₹ value in crores)

Revenue

4903.66

Operating expense

4329.27

Net income

721.31

Net profit margin

14.7%

Earnings per share

3.0

EBITDA

1365.99

Effective tax rate

4.01

(Values in Cr)

Revenue

Net income

Revenue Annual

Particulars

202403 (₹ value in crores)

Revenue

19843.53

Operating expense

17072.26

Net income

2858.18

Net profit margin

14.4%

Earnings per share

11.9

EBITDA

5834.35

Effective tax rate

17.14
Revenue Annual

Particulars

202303 (₹ value in crores)

Revenue

20394.63

Operating expense

16412.32

Net income

1690.72

Net profit margin

8.29%

Earnings per share

7.0

EBITDA

3814.1

Effective tax rate

2.89
Revenue Annual

Particulars

202203 (₹ value in crores)

Revenue

15518.5

Operating expense

14416.51

Net income

-99.99

Net profit margin

-0.64%

Earnings per share

-0.4

EBITDA

2044.91

Effective tax rate

132.58
Revenue Annual

Particulars

202103 (₹ value in crores)

Revenue

13988.4

Operating expense

13362.99

Net income

842.4

Net profit margin

6.02%

Earnings per share

3.5

EBITDA

2359.52

Effective tax rate

1.53
Revenue Annual

Particulars

202003 (₹ value in crores)

Revenue

11906.74

Operating expense

10789.85

Net income

3211.14

Net profit margin

26.96%

Earnings per share

13.38

EBITDA

4222.57

Effective tax rate

1.28

Financials

<p><b>Quarterly</b>: Months listed along the bottom of the graph represent a quarter.</p> <p><b>Annual</b>: Months listed along the bottom of the graph represent a financial year.<br /> </p>

ROE

ROCE

Consolidated Ratios

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

265.36

Return on Equity (ROE)

16.13

Return on Capital Employed (ROCE)

17.2

Total debt to equity ratio

0.08

EBITDA margin

28.63
Consolidated Ratios

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

233.38

Return on Equity (ROE)

16.46

Return on Capital Employed (ROCE)

16.79

Total debt to equity ratio

0.08

EBITDA margin

27.59
Consolidated Ratios

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

200.11

Return on Equity (ROE)

14.5

Return on Capital Employed (ROCE)

17.97

Total debt to equity ratio

0.05

EBITDA margin

29.19
Consolidated Ratios

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

193.65

Return on Equity (ROE)

11.14

Return on Capital Employed (ROCE)

13.6

Total debt to equity ratio

0.13

EBITDA margin

27.8
Consolidated Ratios

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

188.66

Return on Equity (ROE)

9.66

Return on Capital Employed (ROCE)

9.85

Total debt to equity ratio

0.22

EBITDA margin

22.43

ROE

ROCE

Satandalone Data

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

98.76

Return on Equity (ROE)

12.05

Return on Capital Employed (ROCE)

12.22

Total debt to equity ratio

0.4

EBITDA margin

28.78
Satandalone Data

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

98.98

Return on Equity (ROE)

13.89

Return on Capital Employed (ROCE)

16.26

Total debt to equity ratio

0.27

EBITDA margin

32.43
Satandalone Data

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

102.48

Return on Equity (ROE)

-5.19

Return on Capital Employed (ROCE)

7.47

Total debt to equity ratio

0.24

EBITDA margin

24.56
Satandalone Data

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

112.28

Return on Equity (ROE)

3.53

Return on Capital Employed (ROCE)

3.57

Total debt to equity ratio

0.27

EBITDA margin

17.35
Satandalone Data

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

101.68

Return on Equity (ROE)

13.6

Return on Capital Employed (ROCE)

11.85

Total debt to equity ratio

0.27

EBITDA margin

33.69

Financials

<p>Months listed along the bottom of the graph represent a financial year.<br /> </p> <p>         </p> <p><b>Consolidated</b>: Data of the entire group of companies.</p> <p><b>Standalone</b>: Data of the single company.<br /> </p>

(Values in Cr)

Consolidated Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

10520.68

85462.88

85462.88

Total Equity

67105.97

Shares Outstanding

2399334970

Price to book ratio

16.41

Return on assets (%)

11.2

Return on capital (%)

13.69
Consolidated Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

5770.29

80743.59

80743.59

Total Equity

59315.47

Shares Outstanding

2399334970

Price to book ratio

9.93

Return on assets (%)

10.49

Return on capital (%)

12.93
Consolidated Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

5033.35

69807.77

69807.77

Total Equity

51066.11

Shares Outstanding

2399334970

Price to book ratio

8.93

Return on assets (%)

4.68

Return on capital (%)

6.29
Consolidated Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

6445.51

67666.73

67666.73

Total Equity

49479.83

Shares Outstanding

2399334970

Price to book ratio

5.32

Return on assets (%)

4.29

Return on capital (%)

5.48
Consolidated Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

6487.55

68252.46

68252.46

Total Equity

49124.69

Shares Outstanding

2399334970

Price to book ratio

3.46

Return on assets (%)

5.51

Return on capital (%)

6.64

(Values in Cr)

Standalone Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

338.39

41064.79

41064.79

Total Equity

23694.4

Shares Outstanding

2399334970

Price to book ratio

16.41

Return on assets (%)

6.96

Return on capital (%)

8.23
Standalone Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

421.28

40987.49

40987.49

Total Equity

23748.36

Shares Outstanding

2399334970

Price to book ratio

9.93

Return on assets (%)

4.12

Return on capital (%)

5.39
Standalone Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

534.96

40765.48

40765.48

Total Equity

24587.95

Shares Outstanding

2399334970

Price to book ratio

8.93

Return on assets (%)

-0.24

Return on capital (%)

-0.34
Standalone Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

360.98

43734.79

43734.79

Total Equity

26938.47

Shares Outstanding

2399334970

Price to book ratio

5.32

Return on assets (%)

1.92

Return on capital (%)

2.47
Standalone Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

654.78

38410.33

38410.33

Total Equity

24396.22

Shares Outstanding

2399334970

Price to book ratio

3.46

Return on assets (%)

8.36

Return on capital (%)

10.65

Financials

<p>Months listed along the bottom of the graph represent a financial year.</p> <p> </p> <p><b>Consolidated</b>: Data of the entire group of companies.</p> <p><b>Standalone</b>: Data of a single company.<br /> </p>

(Values in Cr)

Net income

Net change

Consolidated Cash Flow

Particulars

Mar 24 (₹ value in crores)

11087.89

Cash from operations

13704.42

Cash from investing

-690.2

Cash from financing

-6710.16

Net change in cash

4734.62

Free cash flow

15906.23
Consolidated Cash Flow

Particulars

Mar 24 (₹ value in crores)

9408.43

Cash from operations

6469.17

Cash from investing

-7943.68

Cash from financing

2376.07

Net change in cash

-608.28

Free cash flow

8554.75
Consolidated Cash Flow

Particulars

Mar 24 (₹ value in crores)

4481.32

Cash from operations

8015.32

Cash from investing

-5724.74

Cash from financing

-5193.46

Net change in cash

-1933.66

Free cash flow

9510.36
Consolidated Cash Flow

Particulars

Mar 24 (₹ value in crores)

2799.37

Cash from operations

7173.31

Cash from investing

536.22

Cash from financing

-5980.48

Net change in cash

726.11

Free cash flow

8343.44
Consolidated Cash Flow

Particulars

Mar 24 (₹ value in crores)

5009.59

Cash from operations

7900.68

Cash from investing

-2588.84

Cash from financing

-5715.14

Net change in cash

-1749.21

Free cash flow

9442.68

(Values in Cr)

Net income

Net change

Standalone Cash Flow

Particulars

Mar 24 (₹ value in crores)

3449.65

Cash from operations

49.45

Cash from investing

-262.91

Cash from financing

473.95

Net change in cash

-81.38

Free cash flow

798.69
Standalone Cash Flow

Particulars

Mar 24 (₹ value in crores)

1741.05

Cash from operations

939.07

Cash from investing

-705.17

Cash from financing

169.31

Net change in cash

-28.78

Free cash flow

1901.5
Standalone Cash Flow

Particulars

Mar 24 (₹ value in crores)

306.86

Cash from operations

5476.82

Cash from investing

-2702.1

Cash from financing

-4870.85

Net change in cash

63.41

Free cash flow

6326.71
Standalone Cash Flow

Particulars

Mar 24 (₹ value in crores)

855.57

Cash from operations

-178.84

Cash from investing

1463.81

Cash from financing

-999.73

Net change in cash

47.57

Free cash flow

629.23
Standalone Cash Flow

Particulars

Mar 24 (₹ value in crores)

3253.0

Cash from operations

1642.9

Cash from investing

1479.29

Cash from financing

-2871.15

Net change in cash

-86.01

Free cash flow

2214.71

Financials

<p>Months listed along the bottom of the graph represent a financial year.</p> <p> </p> <p><b>Consolidated</b>: Data of the entire group of companies.</p> <p><b>Standalone</b>: Data of a single company.<br /> </p>

Company name

Price

P/E

P/B

Market cap

52 week low/high

38.57

20.74

2.1

295.57

34.11 / 77.7

121.65

15.21

1.22

1281.83

92.25 / 184.95

1454.5

22.28

3.76

117471.3

1310.05 / 1702.0

299.95

24.85

3.04

882.78

145.0 / 449.0

₹38.57

23.23

6.55

295.57

34.11 / 77.7

₹684.05

38.91

6.05

1977.63

548.05 / 861.4

₹7920.85

118.13

29.14

19802.13

5415.55 / 9199.0

₹121.65

18.57

1.21

1281.83

92.25 / 184.95

Sun Pharmaceutical IndL technical summary

1731.81.4
11
5
Bullish
1723.3
1735.1
1738.7
1745.0
1744.9
1740.6
1743.1
1713.4
1724.2
1730.1
1746.4
1769.6
1754.9
1727.3
1743.2
1781.2
1719.7
PIVOT
First support1691.4
Second support1675.0
Third support₹1646.7
RSI43.57
MACD-6.23%
Commodity Channel Index (CCI)₹-78.02
First resistance1736.1
Second resistance1764.4
Third resistance-1780.8
ADX31.58
Williams % R-63.01
Date2025-05-20
Same day1933363
Week1859434
Month1575145
1 year
10.82
3 years
23.09
Price change analysis
-0.45%
Over 1 month
--2.12%
Over 3 month
-2.3%
Over 6 month
--4.05%
Over 3 year
23.09%
Over 6 year
30.23%

Sun Pharmaceutical IndL shareholding pattern

Holding %

Public

8.86%

Promoter holdings

54.47%

FII

17.95%

DII

18.69%

Promoter shares

0.88%

Promoter shares

Shanghvi Finance Private Limited

Dilip.s.shanghvi

Icici Prudential Value Discovery Fund

Life Insurance Corporation Of India

Sbi Nifty 50 Etf

Aditya Medisales Limited

Raksha Sudhir Valia

Nps Trust- A/c Hdfc Pension Fund Management Limited Scheme E - Tier I

Hdfc Trustee Company Ltd. A/c Hdfc Balanced Advantage Fund

Lakshdeep Investments & Finance (p) Ltd.

Sudhir V. Valia

Unimed Investments Limited

Vibha Dilip Shanghvi

Vidhi Dilip Shanghvi

Aalok Dilip Shanghvi

Shanghvi Family & Friends Benefit Trust

Gujarat Sun Pharmaceutical Industries Pvt Ltd

Sanghvi Properties Private Limited

Flamboyawer Finance Private Limited

Kumud Shantilal Shanghvi

Share

Category

967051732
(40.3)%

Shareholding of Promoter and Promoter Group

230385155
(9.6)%

Shareholding of Promoter and Promoter Group

80329300
(3.35)%

Public Shareholding

72886584
(3.04)%

Public Shareholding

49030961
(2.04)%

Public Shareholding

40153960
(1.67)%

Shareholding of Promoter and Promoter Group

28830352
(1.2)%

Shareholding of Promoter and Promoter Group

28679713
(1.2)%

Public Shareholding

27121088
(1.13)%

Public Shareholding

24418497
(1.02)%

Public Shareholding

14345019
(0.6)%

Shareholding of Promoter and Promoter Group

10400850
(0.43)%

Shareholding of Promoter and Promoter Group

8840280
(0.37)%

Shareholding of Promoter and Promoter Group

2822427
(0.12)%

Shareholding of Promoter and Promoter Group

2877280
(0.12)%

Shareholding of Promoter and Promoter Group

1276774
(0.05)%

Shareholding of Promoter and Promoter Group

14362
(0)%

Shareholding of Promoter and Promoter Group

15479
(0)%

Shareholding of Promoter and Promoter Group

20865
(0)%

Shareholding of Promoter and Promoter Group

100000
(0)%

Shareholding of Promoter and Promoter Group

About Sun Pharmaceutical IndL

Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. The company has global presence with 43 manufacturing facilities across the world. India and the US are two predominant markets, accounting for nearly 70% of the company's revenue. The company has a robust product pipeline and established presence in Europe and high-growth emerging markets like Russia, Romania, South Africa, Brazil and Mexico. The company has entered into a joint-venture agreement with MSD (Merck) to develop and bring differentiated branded generics to emerging markets. Sun Pharmaceutical Industries invests around 7-8% of its global revenue each year in R&D. The R&D capabilities span the development of differentiated products such as liposomal products, inhalers, lyophilized injections and nasal sprays, besides controlled release dosage forms. Sun Pharmaceutical Industries Limited was incorporated in 1983. The company began operations in Kolkata with just 5 products to treat psychiatry ailments. They set up a compact manufacturing facility for tablets/capsules at Vapi. Sales were initially limited to two states in Eastern India. In the year 1986, the company set up an administrative office in Mumbai. They extended the customer coverage to select cities in Western India. In the year 1987, they rolled out their marketing operations nation-wide. In the year 1988, the company launched Monotrate and Angizem products. In the year 1989, they introduced Products used in gastroenterology. They moved their corporate office to Baroda. Also, they began exporting their products to neighboring countries. In the year 1998, the company established their first research center, SPARC and this created the base for strong product and process development that enabled growth in the subsequent years. Also, they began office in Moscow. In the year 1994, the company was listed on the main stock exchanges in India. They started production in a dosage form plant at Silvassa. Also, they completed the major expansion at Vapi plant. In the year 1995, the company's first API plant at Panoli started production. Also, a new division, Azura, was begun for cardiology products. Inca, a new division to market critical care medication to intensive care units began operations. They strengthened the international marketing with offices in Ukraine and Belarus. In the year 1996, the company acquired an API plant at Ahmednagar from the multinational Knoll Pharmaceutical, and expanded and substantially upgraded for regulated markets, with capacity addition over the years across differentiated API lines such as anticancers and peptides. Also, the company acquired equity stake in Gujarat Lyka Organics Ltd., a manufacturer of Cephalexin Active with a USFDA approval for the intermediate, 7ADCA. In the year 1997, the company's headquarters was shifted to Mumbai, India's commercial capital. Also, they began the first of their international acquisitions with an initial $7.5 million investment in Caraco, Detroit. Also, they took equity stake in MJ Pharma, a manufacturer of several dosage form lines with UK MHRA approval for Cephalexin capsules. The company acquired TDPL with an extensive product offering and its portfolio streamlined. In the year 1998, the company acquired a basket of products, including several respiratory/asthma brands acquired from Natco Pharma. Their new formulation plant at Silvassa commenced operations. In the year 2001, the company built a new formulation plant in Dadra. Also, the erstwhile TDPL division was renamed Spectra. A new division, Arian, targeting cardiologists/physicians and diabetologists, was launched. In the year 2004, the company acquired common stock and options from 2 large shareholders of Caraco, increasing stake to over 60% from 44% at a total outlay of about $42 million. The upgraded and expanded formulation site in Halol, India (the erstwhile MJ Pharma site) received approval from USFDA, UK MHRA, South African MCC, Brazilian ANVISA and Columbian INVIMA. During the year, the company completed the construction at a formulation manufacturing site at Jammu. They commissioned their first joint venture manufacturing unit, in Dhaka, Bangladesh. Also, two of their API factories received USFDA approval, taking the total number of US FDA approved sites to three. The company acquired a Cephalosporin Active manufacturer, Phlox Pharma, with European approval for cefuroxime axetil amorphous. In December 2004, a research centre spread over 16 acres was inaugurated by the President of India, with special lab space for drug discovery and innovation. In the year 2005, the company bought a plant in Bryan, Ohio, US and the business of ICN, Hungary from Valeant Pharma. In December 2005, they acquired the intellectual property and assets of Able Labs from the US District Bankruptcy court in New Jersey. In the year 2007, the company de-merged the innovative research and business into a new company, SPARC Ltd. SPARC Ltd was listed on the stock exchanges in India, the first pure research company to be so listed. In May 2007, the company along with their subsidiaries, signed definitive agreements to acquire Taro Pharmaceutical Industries Ltd., a multinational generic manufacturer with established subsidiaries, manufacturing and products across the US, Israel, Canada for $454 million. In November 2008, the company along with their subsidiaries acquired 100% ownership of Chattem Chemicals, Inc., a narcotic raw material importer and manufacturer of controlled substances with an approved API facility in Tennessee. This offers vertical integration for its controlled substance dosage form business in the US. In September 2010, the company acquired Taro Pharmaceuticals. This acquisition doubled the size of their US business and brought them a range of generics including a strong line of dermatologicals. In April 2011, MSD in India and Sun Pharmaceutical Industries Ltd announced formation of an India-specific strategic partnership agreement under which Sun Pharma will have the right to market, promote and distribute MSD's diabetes products, sitagliptin and sitagliptin plus metformin, under different brand names in India. In June 14, 2011, Caraco Pharmaceutical Laboratories Ltd (Caroco) merged with a subsidiary of the company. Thus, Caraco became a wholly owned subsidiary of the company. In 2012, Sun Pharma bagged USFDA approval for its AND Application for generic Zyprexa. The company also acquired URL generic business from Takeda during the year under review. In 2013, the company announced US FDA approval for generic Cymbalta. The company and Intrexon formed Joint Venture to Develop New Class of Therapeutics for Ocular Diseases. The Company announces USFDA approval for generic Prevacid, generic DoxilAr and generic DepoAr-Testosterone Injection. The company also Announces 1:1 Bonus during the year. The company also announces Tentative USFDA approval for generic Januvia & Glumetza. In 2014, the company announced US FDA approval for generic Temodar. The company acquires Pharmalucence during the year. The company and Merck & Co. Inc. enter into Licensing Agreement for Tildrakizumab during the year under review. The Board of Directors of the Company at its Meeting held on April 06, 2014 has approved the scheme of arrangement between Ranbaxy Laboratories Limited and the Company under the provisions of the sections 391 to 394 and other applicable provisions of the Companies Act, 1956 and corresponding provisions of the Companies Act, 2013 subject to receipt of necessary approvals, consents and filings. In 2015, the company receives US FTC clearance for Ranbaxy acquisition. The company and AstraZeneca enter into distribution agreement for ticagrelor in India during the year. SPARC Licenses Xelpros (Latanoprost BAK-free) to Sun Pharma. During the year, Hon'ble High Court of Gujarat, at Ahmedabad has approved the Scheme of Amalgamation of Sun Pharma Global Inc. (SPGI), wholly-owned subsidiary of the Company. The company also announces US FDA Approval for Ximino TM. The company also announces another successful completion of Opiates business acquisition in Australia and also acquires InSite Vision Incorporated. The company announces Absorica patent litigation settlement during the year under review. On 10 December 2015, Sun Pharmaceutical Industries announced that it has entered into a tripartite research and option agreement with Israel-based Weizmann Institute of Science and Spain's Health Research Institute of Santiago de Compostela (IDIS) to develop breakthrough products for the treatment of neurological diseases like brain stroke as well as glioblastoma, a lethal brain cancer. On 14 December 2015, Sun Pharmaceutical Industries announced that as a part of its manufacturing consolidation in the US, one of its wholly owned subsidiaries has entered into an agreement with Nostrum Laboratories Inc. (Nostrum) for the divestment of the Bryan (Ohio) unit in the US. As a part of the agreement, the Sun Pharma subsidiary has divested this unit as a going concern along with the employees and related products to Nostrum. On 19 December 2015, Sun Pharmaceutical Industries announced that it has received a Warning Letter from the USFDA as a result of the September 2014 inspection for its facility located at Halol, Gujarat in India. Post the September 2014 inspection, the US FDA has withheld future product approvals from the Halol facility. Sun Pharma said that the company expects to request a re-inspection by USFDA upon completion of its remediation commitments. Sun Pharma also said at that time that the Halol facility will continue to supply important drug products to meet its obligations to its customers and the patients who use the drugs in the United States and around the world. On 23 March 2016, Sun Pharma and AstraZeneca Pharma India Limited announced a partnership for the distribution of dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is AstraZeneca India's leading diabetes medicine. Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name Oxra. AstraZeneca India markets dapagliflozin under the brand name Forxiga and under the terms of the agreement, both companies will promote, market and distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights to dapagliflozin. Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name Oxramet after requisite regulatory approval. On 29 March 2016, Sun Pharma announced the acquisition of 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan. According to the agreements entered into between the parties, a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of US$ 293 million. These brands have combined annualized revenues of approximately US$ 160 million and address medical conditions across several therapeutic areas. Under the terms of the agreements, Novartis will continue to distribute these brands, for a certain period, pending transfer of all marketing authorizations to Sun Pharma's subsidiary. The acquired brands will be marketed by a reliable and established local marketing partner under the Sun Pharma label. The local marketing partner will also be responsible for distribution of the brands. On 4 May 2016, Sun Pharma and International Centre for Genetic Engineering and Biotechnology (ICGEB) signed an agreement to develop a novel botanical drug for treatment of dengue. Through this agreement Sun Pharma will follow up on earlier pre-clinical collaboration between ICGEB and erstwhile Ranbaxy Laboratories. Sun Pharma will develop Cipa, a botanical drug following a drug registration process similar to a new chemical entity, consisting of all required in-vitro, in-vivo, pre-clinical and clinical studies meeting all regulatory standards of India and other regulatory agencies worldwide. A botanical drug is a plant-derived medicinal product that is intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans. On 4 June 2016, Sun Pharma announced that as a part of its manufacturing consolidation in the US, one of its wholly owned subsidiaries has entered into an agreement with Frontida BioPharm, Inc. (Frontida) for divestment of its two oral solid dosage manufacturing facilities located at Philadelphia, PA, and Aurora, IL, both in the US, along with 15 related pharmaceutical products. In connection with the transaction, Frontida has agreed to continue manufacturing certain products for Sun Pharma at these facilities on a contract basis for a predetermined period. The Board of Directors of Sun Pharma at its meeting held on 23 June 2016 approved buyback of fully paid up equity shares of the company through the tender offer route at Rs 900 per share. The purpose of the buyback is to return surplus funds to the equity shareholders and thereby, enhancing the overall returns to shareholders. On 18 July 2016, Sun Pharma and Sun Pharma Advanced Research Company Ltd. (SPARC) announced a licensing arrangement for SPARC's ELEPSIA XR (Levetiracetam Extended Release tablets). As per the agreement, SPARC will license ELEPSIA to a wholly-owned subsidiary of Sun Pharma for the US market. SPARC will receive an up-front payment of US$10 million from Sun Pharma. It is also eligible for certain additional milestone payments and defined royalties linked to any future sales of ELEPSIA XR. On 27 July 2016, Sun Pharma and Almirall announced a licensing agreement on the development and commercialization of tildrakizumab for psoriasis in Europe. Under terms of the license agreement, Almirall will pay Sun Pharma an initial upfront payment of US $50 million. Sun Pharma will be eligible to receive development and regulatory milestone payments and, additionally, sales milestone payments and royalties on net sales. Almirall will be able to lead European studies, and participate in larger global clinical studies for psoriasis indication subject to the terms of the Sun Pharma - Merck agreements, as well as certain cost sharing agreements. Sun Pharma will continue to lead development of tildrakizumab for other indications, where Almirall will have right of first negotiation for certain indications in Europe. On 6 September 2016, Sun Pharma announced that it has signed a strategic distribution alliance with Mitsubishi Tanabe Pharma Corporation, Japan for 14 prescription brands. Under this alliance, Mitsubishi Tanabe Pharma Corporation will market and distribute all the 14 brands as well as provide information on their proper use to healthcare professionals. On 19 October 2016, Sun Pharma and International Centre for Genetic Engineering and Biotechnology (ICGEB) announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans. According to the agreement, Sun Pharma will fund and support further development of the vaccine candidate and existing ICGEB Know-How and Patents. ICGEB will grant Sun Pharma exclusive rights and licenses for development and commercialization of this vaccine globally. ICGEB will receive pre-defined royalty and milestone payments. On 26 October 2016, Sun Pharmaceutical Industries announced the execution of definitive agreements by its wholly owned subsidiary for the acquisition of 100% of Ocular Technologies, Sarl (OTS), a portfolio company of Auven Therapeutics (Auven), an international private equity company focused on accelerated development of breakthrough therapeutic drugs. OTS owns exclusive, worldwide rights to Seciera (cyclosporine A, 0.09% ophthalmic solution). Sun Pharma will pay Auven US$ 40 million upfront, plus contingent development milestones and sales milestones as well as tiered royalty on sales of Seciera as consideration for this acquisition.On 23 November 2016, Sun Pharma announced the execution of definitive agreements by its wholly owned subsidiary for the acquisition of 85.1% ofJSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. The equity consideration for the 85.1% stake is US$ 24 million. Sun Pharma would also assume a debt of approximately US$ 36 million as part of this transaction. Biosintez is a Russian pharmaceutical company focusing on the hospital segment with annual revenues of approximately US$ 52 million for 2015. It has a manufacturing facility in Penza region with capabilities to manufacture a wide variety of dosage forms including pharmaceuticals for injections, blood substitutes, blood preservatives, ampoules, tablets, ointment, creams, gels, suppositories, APIs, etc. On 28 November 2016, Sun Pharma announced the launch of a branded ophthalmic product BromSite 0.075% in the US market. It was the first branded product launched by the company in the USA following its focus on Specialty Business. On 12 December 2016, Sun Pharma and Israel-based Moebius Medical announced that they have entered into an exclusive worldwide licensing deal to further develop MM-II, a novel pharmaceutical candidate for the treatment of pain in osteoarthritis. According to the agreement, Sun Pharma will fund further development of Moebius Medical's lead product, MM-II, and undertake its global commercialization. Moebius Medical will conduct requisite pre-clinical studies, and will assume responsibility for product development and manufacturing through the end of Phase-II studies. Sun Pharma will assume responsibility for further clinical studies, regulatory submissions and product commercialization. Moebius Medical will receive an upfront payment, development-based and sales-based milestone payments, and tiered royalties on sales from Sun Pharma. On 22 December 2016, Sun Pharma announced its plans to acquire a branded oncology product Odomzo from Novartis. The agreement was signed for an upfront payment of US$ 175 million and additional milestone payments. Odomzo (Sonidegib) was approved by the USFDA in July 2015. Odomzo is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. On 4 January 2017, Sun Pharma announced successful Phase 3 confirmatory clinical trial results for Seciera for the treatment of dry eye disease. Seciera is being developed by Ocular Technologies, a company acquired by Sun Pharma. Following this acquisition, Sun Pharma owns exclusive, worldwide rights to Seciera and is developing it to commercialize for global markets including US, Europe, and Japan, as well as several emerging markets. On 14 March 2017, Sun Pharmaceutical Industries announced that USFDA will lift the Import Alert imposed on the company's Mohali, Punjab manufacturing facility and remove the facility from the Official Action Initiated (OAI) status. This proposed action will clear the path for Sun Pharma to supply approved products from the Mohali facility to the US market, subject to normal USFDA regulatory requirements. The Mohali facility was inherited by Sun Pharma as part of its acquisition of Ranbaxy Laboratories in 2015. The USFDA had taken action against the Mohali facility in 2013 when it ordered the facility to be fully subject to Ranbaxy's Consent Decree of Permanent Injunction. Certain conditions of the consent decree will continue to be applicable to the Mohali facility. On 27 June 2017, Sun Pharmaceutical Industries and National Institute of Virology (NIV), Pune, an institution of the Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, New Delhi announced that they have signed an agreement for testing phytopharmaceutical, biologic and chemical entities developed by Sun Pharma against Zika, Chikungunya and Dengue viruses. Sun Pharma will provide drug molecules to NIV for testing against Zika, Chikungunya and Dengue in model systems. Candidate molecules with encouraging data will then be taken forward for commercial development. On 4 July 2017, Sun Pharmaceutical Industries and Samsung BioLogics announced a strategic long-term manufacturing agreement for Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis. According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab. The approximate value of the contract will be US$ 55.5 million. The regulatory filings associated with tildrakizumab have been accepted for review by the U.S. Food and Drug Administration and the European Medicines Agency (EMA). On 16 January 2018, Sun Pharmaceutical Industries announced that its wholly owned subsidiaries have reached an agreement with Ironwood Pharmaceuticals, Inc. and Allergan plc to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Linzess (Linaclotide capsules) in the US. Pursuant to the terms of the settlement, Ironwood Pharmaceuticals and Allergan will grant, the wholly owned subsidiaries of Sun Pharma, a license to market a generic version of Linzess in the United States beginning 01 February 2031 (subject to USFDA approval) or earlier under certain circumstances. During the FY2019, Sun Pharma has received USFDA approval for its New Drug Application (NDA) of XELPROSTM (latanoprost ophthalmic emulsion 0.005%) used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. XELPROSTM is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK), a commonly used preservative in topical ocular preparations. XELPROSTM was launched in the US in January 2019. The company has launched ILUMYATM (tildrakizumab-asmn) 100 mg/mL in the US for treating moderate-to-severe psoriasis in October 2018. The company has received a good initial response for the product and we expect ramp-up in ILUMYATM sales in the US over the next few years. The company also commenced a direct-to-consumer advertising initiative for ILUMYATM in the US. Sun Pharma also received approval from the Australian Therapeutic Goods Administration (TGA) for ILUMYATM during the year. The product has already been commercialised in Australia. During the year 2018-19 the company received USFDA approvals for CEQUATM (cyclosporine ophthalmic solution 0.09%). CEQUATM increases tear production in patients with dry eyes. It is the first and only approved dry eye treatment to combine cyclosporine A with nanomicellar technology. CEQUATM will be commercialised in the US in FY20. In July 2018, Sun Pharma announced the USFDA approval for INFUGEMT (gemcitabine in 0.9% sodium chloride injection), for intravenous use in a ready-to-administer (RTA) bag. INFUGEMT uses a proprietary technology, which allows cytotoxic oncology products to be pre-mixed in a sterile environment and supplied to the prescribers in RTA infusion bags. These RTA bags will provide greater safety, by preventing problems of over-dosing or under-dosing and eliminating contamination risk. INFUGEMT was commercialised in the US in April 2019. During the fiscal 2020, Sun Pharma announced licensing agreements with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialisation of two of its specialty products - Tildrakizumab (for psoriasis and psoriatic arthritis) and Cyclosporine A 0.09% (CsA) eye drops (for dry eye disease) in Greater China. In July 2019, Sun Pharma announced the US launch of EZALLOR SPRINKLET (Rosuvastatin) capsules for the treatment of three types of elevated lipid disorders in people who have difficulty swallowing, a problem that is estimated to affect approximately 30-35% of long-term care residents. With the introduction of EZALLOR SPRINKLE, Sun Pharma continued its commitment of providing a portfolio of innovative formulation products to address the needs of a specific patient segment. In August 2019, Sun Pharma announced the filing of an application in Japan for manufacturing and marketing authorisation of ILUMYA (Tildrakizumab) for moderate-to-severe psoriasis with the Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Sun Pharma is committed to growing its global dermatology franchise, with ILUMYATM as its lead product. Further in August 2019, Sun Pharma entered into a global licensing agreement with the CSIR - Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT), for patents related to certain compounds with potential therapeutic activity across multiple indications in Sun Pharma's specialty focus areas. In August 2019, Sun Pharma granted an exclusive license to a subsidiary of China Medical System Holdings Ltd. (CMS) to develop and commercialise seven generic products in Mainland China. Till date, Sun Pharma and the CMS collaboration covers a total of eight generic products, with an addressable market size of about USD 1 Billion (as per IQVIA data) in Mainland China. This collaboration gives Sun Pharma an entry into the Chinese generic pharmaceutical market. In October 2019, the Company commercialised CEQUA (cyclosporine ophthalmic solution) 0.09% in the US. It launched DRIZALMA SPRINKLE (duloxetine delayed-release capsules) in the US for oral use. In November 2019, Sun Pharma entered into a licensing agreement with AstraZeneca UK Ltd. (AstraZeneca) to introduce certain novel ready to use (RTU) infusion oncology products in China. In January 2020, Sun Pharma entered into exclusive licensing and supply agreements with Rockwell Medical Inc. (Rockwell), to commercialise Rockwell's Triferic, a proprietary iron replacement and haemoglobin maintenance drug, for treating anaemia in hemodialysis patients in India. In February 2020, Sun Pharma launched ABSORICA LDT (isotretinoin) capsules in the US for the management of severe recalcitrant nodular acne in patients 12 years of age and older. ABSORICA LD is the only isotretinoin formulation to feature Sun Pharma's micronisation technology, which utilises micronised particles to optimise absorption at a 20% lower dose. In March 2020, Sun Pharma committed to donate Hydroxychloroquine (HCQS), Azithromycin, and other related drugs and hand sanitisers to support India's COVID-19 response. It also donated HCQS in the US market. In March 2020, Sun Pharma launched a buyback offer in India to buy back 40 Million shares at a price up to Rs 425 per equity share, totalling to about Rs 17 billion. In 2021, the Company launched ILUMYA, an innovative drug in Japan. It commenced Phase-3 clinical trials for psoriatic arthritis. It initiated Phase-2 clinical trials for a potential oral treatment for atopic dermatitis and moderate to severe plaque psoriasis. It commenced Phase-2 trials for a potential treatment for knee pain in patients with symptomatic knee osteoarthritis. During the year 2021, Company launched 96 products in the domestic market, including the anti-epileptic Brevipil (Brivaracetam) and FluGuard (Favipiravir). It supplied drugs like Remdesivir, Itolizumab, Hydroxychloroquine (HCQS), Favipiravir and Liposomal Amphotericin B in the market for treatment of COVID-19 and associated ailments. National Company Law Tribunal (NCLT) vide its Order dated August 31, 2021, sanctioned the Scheme of Amalgamation and Merger of Sun Pharma Global FZE (Transferor Company), an indirect wholly owned subsidiary of the Company with Sun Pharmaceutical Industries Limited (Company), which inter-alia, envisages merger of Sun Pharma Global FZE into the Company, effective from October 1, 2021 with appointed date as January 1, 2020. The Board of Directors of the Company at its meeting held on May 30, 2022 has approved the Scheme of Amalgamation of Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited, Skisen Labs Private Limited, Wholly-owned Subsidiaries of the Company with the Company. During the year 2022, the Company entered into License and Supply Agreements for Winlevi (clascoterone cream 1%) with Cassiopea SpA. Winlevi was approved by the United States Food and Drug Administration (USFDA) in August-2020 as a novel drug mechanism for the topical treatment of acne in patients 12 years and older. In March 2022, Sun Pharma reiterated the clinical profile of Winlevi by presenting data from two pivotal Phase 3 clinical trials of Winlevi for the topical treatment of acne vulgaris. During the year 2022, the Company received final USFDA approval for its Abbreviated New Drug Application (ANDA) for generic Amphotericin B Liposome for injection, 50 mg/vial single-dose vial. In June 2021, Sun Pharma entered into an agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, for a generic version of Revlimid (lenalidomide capsules) in the US. In June 2021, Sun Pharma and Ferring Pharmaceuticals entered into licensing agreement for co-marketing CARITEC, an innovative obstetric drug for preventing post-partum haemorrhage (PPH). In September 2021, Sun Pharma launched a novel formulation in cough syrup, Chericof 12 in India. During year 2022-23, Company acquired Concert Pharmaceuticals, Inc. to strengthen global specialty product portfolio of Company. It launched Sezaby in the US specifically indicated to treat seizures in infants; launched Odomzo; launched Cequa to expand commercial footprint and bring the global specialty portfolio to home market. In 2024, Company launched a novel ophthalmology treatment, CEQUAr, in India for patients who have Dry Eye Disease (DED) with inflammation, a commonly occurring condition. It further launched Revital Cal 500, a calcium with a superior formulation to participate in the growing calcium supplements market.

Parent Organisation

Sun Pharma

NSE Symbol

SUNPHARMA

Founded

1993

View more stocks

IOL CHEM AND PHARMA LTD

₹86.27

8.98%

GLAXOSMITHKLINE PHARMA LT

₹2984.2

7.09%

CAPLIN POINT LAB LTD.

₹2252.4

5.89%

MARKSANS PHARMA LIMITED

₹250.21

5.67%

SEQUENT SCIENTIFIC LTD.

₹178.73

5.5%

MOREPEN LAB. LTD

₹65.94

4.94%

GLAND PHARMA LIMITED

₹1571.3

4.87%

VENUS REMEDIES LIMITED

₹349.9

4.83%

INFINIUM PHARMACHEM LTD

₹315.0

4.61%

MEGASOFT LTD

₹78.8

4.1%

Popular stocks

Rail Vikas Nigam
Suzlon Energy
NHPC
Yes Bank
TATA Motors
BHEL
HDFC Bank
State Bank of India
TATA Power
TATA Steel
NBCC India
Infosys India
Adani Power
IFCI
Coal India
OLA Electric

What’s trending

Top gainers Top losers 52-week high 52-week low All stocks

All stocks

DYNAMIND

DYNAMIC INDUSTRIES LTD.

120.37

+20.06 +20%

ADDIND

ADDI INDUSTRIES LTD.

80.64

+13.44 +20%

NAHARPOLY

NAHAR POLYFILMS LTD.

262

+41.35 +18.74%

NAHARPOLY

NAHAR POLY FILMS LIMITED

261.99

+40.61 +18.34%

View all

Top gainers

INDUSINDBK

INDUSIND BANK LIMITED

793.9

+23.95 +3.11%

TATASTEEL

TATA STEEL LIMITED

162.69

+1.05 +0.65%

JIOFIN

JIO FIN SERVICES LTD

275.8

+1.45 +0.53%

BHARTIARTL

BHARTI AIRTEL LIMITED

1831.5

+9.00 +0.49%

View all

Top losers

POWERGRID

POWER GRID CORP. LTD.

289.3

-6.85 -2.31%

TRENT

TRENT LTD

5348

-95.50 -1.75%

ITC

ITC LTD

425.5

-7.50 -1.73%

RELIANCE

RELIANCE INDUSTRIES LTD

1406.3

-22.90 -1.60%

View all

Frequently asked questions

What is share price of SUN PHARMACEUTICAL IND L?
<p> As of May 22 2025 10:47 AM, at May 22 2025 10:47 AM, the SUN PHARMACEUTICAL IND L share price stands at Rs.1720.9.</p>
What is the market cap of SUN PHARMACEUTICAL IND L?
<p>As of May 22 2025 10:47 AM, the market cap of SUN PHARMACEUTICAL IND L stands at Rs.415516.8 Cr. <br /> </p>
What is the PE and PB ratio of SUN PHARMACEUTICAL IND L?
<p> The PE and PB ratios of SUN PHARMACEUTICAL IND L is 130.03 ratio and 98.33 ratio as of May 22 2025 10:47 AM.</p>
What is the 52 week high and low of SUN PHARMACEUTICAL IND L?
<p>The 52 week high and low of SUN PHARMACEUTICAL IND L is Rs.1960.35 and Rs.1377.2 as of May 22 2025 10:47 AM.<br /> </p>
How can I buy SUN PHARMACEUTICAL IND L share?
<p>You can easily buy&nbsp;SUN PHARMACEUTICAL IND L shares on&nbsp;the <b>Bajaj Broking</b> platform by opening a Demat account&nbsp;and verifying your KYC documents online. There are no account opening charges for a Demat account with Bajaj Broking.<br> </p>
Show More Text Show Less Text

Related articles

Article 1

How to Buy Shares

Jan 30, 2025

Read More

share-market-timings-in-india 2

Share Market Timings in India

May 15, 2023

Read More

what-is-trading 3

What is Trading

Mar 25, 2025

Read More

what-is-demat-account 4

What is Demat Account: Meaning, Types & Benefits

May 25, 2021

Read More


Related videos

Features and benefits of Demat Account
 
 

Features and benefits of Demat Account

How to open a Demat and Trading account with us
 
 

How to open a Demat and Trading account with us

Stock market basics for beginners
 
 

Stock market basics for beginners

Features and Benefits of a Trading account
 
 

Features and Benefits of a Trading account

Different types of Demat accounts
 
 

Different types of Demat accounts


Related tags

Top gainers
Top losers
52 week high
52 week low
All stocks

You are here

  1. Home
  2. Investments
  3. Sun Pharmaceutical IndL Share Price

Related links

  • Investments
  • Brokerage calculator
  • Demat account
  • Trading account

Disclaimer

*Disclaimer for Bajaj Finance Limited (‘BFL’):

Stock trading business is carried by Bajaj Financial Securities Limited ("BFSL"), a broker and Depository Participant registered with Securities Exchange Board of India and offers various products/services related to Securities market (Securities market products/services). BFL merely facilitates display of data shared by BFSL on its webpage/mobile application. Such data received from BFSL, or any of its service providers is on “as is” basis. BFL does not make any representation or warranty, express or implied, regarding accuracy, completeness of such data displayed herein.

When you opt to avail the Securities market products/services of BFSL by clicking on the BFSL weblink/mobile app, you will be redirected to BFSL's web page/mobile app for initiation and completion of the transaction. You are supposed to exercise independent diligence by reading all the related documents carefully before deciding to invest in Securities market Products/services.

BFL is a Non-Banking Financial Company carrying the business of acceptance of deposits and providing lending solutions to Retail and Corporate customers. BFL does not offer nor advice on Securities market products/services and shall not be liable or responsible for any of your investment decision."
 

**Disclaimer: For Bajaj Financial Securities Limited

Investments in securities market are subject to market risk, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. All leveraged intraday positions will be squared off the same day. There is no restriction on withdrawal of unutilised margin amount. Trade Recommendations are research-calls provided under the SEBI Research Analyst guidelines. Visit https://www.bajajbroking.in/disclaimer for complete disclaimer.

Securities market Products/services are made available only at the discretion of BFSL and subject to the individual contractual terms and conditions of the respective Securities market products/services. You shall be the sole owner of any decision to invest in any BFSL's Securities market products/services.

Securities market products/services may be withdrawn or amended at any time by BFSL without notice and your recourse in such case would be directly to reach out BFSL at connect@bajajfinserv.in or 1800 833 8888.


Powered by Bajaj Financial Securities Limited (Bajaj Broking)

Go To Top

Application Forms

  • Personal Loan
  • Business Loan
  • Home Loan
  • Gold Loan
  • Insta EMI Card
  • Wallet Care
  • Health Insurance
  • Loan for Doctors
  • Fixed Deposit
  • Loan Against Property
  • Loan for Chartered Accountants
  • Open Demat Account
  • Two-wheeler Loan
  • New Car Finance
  • Used Car Loan
  • Loan Against Car
  • Car Loan Balance Transfer and Top-up
  • Mutual Fund
  • Secured Business Loan
  • Loan for Lawyer

Products Portfolio

Loans

  • Personal Loan
  • Insta Personal Loan
  • Business Loan
  • Home Loan
  • Gold Loan
  • MSME Loan
  • Mortgage Loan
  • Loan Against Property
  • Two & Three Wheeler Loan
  • Education Loan on Property
  • Personal Loan for Self-employed Individuals
  • Two-wheeler Loan
  • New Car Finance
  • Used Car Loan
  • Loan Against Car
  • Car Loan Balance Transfer and Top-up
  • Used Cars and Loan

Insurance

  • Health Insurance
  • Car Insurance
  • Pocket Insurance
  • Investment Plans
  • Appliances Extended Warranty
  • Pocket Subscription

Finance for Professionals

  • Loan for Doctors
  • Loan for Chartered Accountants

Investments

  • Fixed Deposit
  • Open Demat Account
  • Mutual Funds
  • NFO (New Fund Offer)
  • ELSS Mutual Funds
  • Equity Mutual Funds
  • Hybrid Mutual Funds
  • Debt Mutual Funds
  • Multi Cap Mutual Funds
  • Large Cap Mutual Funds
  • Mid Cap Mutual Funds
  • Small Cap Mutual Funds
  • Liquid Mutual Funds
  • Aggressive Hybrid Mutual Funds

Pocket Subscription

  • Mobile Protection Plan
  • Wallet Care
  • Fonesafe Lite
  • Neuro Care Plan
  • Health Prime Max
  • Cpp Road Assist
  • Healthy Body Package

Bajaj Mall

  • Smartphones
  • Mattress
  • Smartwatches
  • Cycles
  • Music & Audio
  • Speakers
  • Water Purifiers
  • Laptops
  • Two-wheeler
  • Washing Machine
  • Televisions
  • Air Conditioner
  • Refrigerators
  • Furniture

Services

  • Sign-in to our Customer Portal (My Account)
  • Manage your Profile
  • Manage your Mandate
  • Manage your Loans
  • Manage your Flexi Loans
  • Manage your Insta EMI card
  • Manage your Fixed Deposit

Wallets & Cards

  • Wallet
  • Bajaj Finserv Insta EMI Card

Value Added Services

  • Credit Pass
  • Gold Rate

Payments

  • All Payments
  • Wallet
  • UPI
  • Mobile recharge
  • Electricity Bill Payment
  • DTH Recharge
  • Loan Repayment
  • Gas Booking
  • Rewards
  • Bajaj Pay FASTAg
  • Bajaj Pay Wallet KYC Upgrade
  • Bajaj Pay FASTAg Registration
  • Bajaj Pay FASTag Replacement
  • Bajaj Pay FASTag Closure
Pre-approved Offers
Offers & Promotions
Article and Insights

Calculators

  • Personal Loan EMI Calculator
  • Home Loan EMI Calculator
  • Home Loan Eligibility Calculator
  • Business Loan EMI Calculator
  • Personal Loan Eligibility Calculator
  • Loan Against Property EMI Calculator
  • Education Loan on Property Calculator
  • FD Calculator
  • Gratuity Calculator
  • Income Tax Calculator
  • Top-up Loan Calculator
  • Part-prepayment Calculator
  • GST Calculator
  • Gold Loan Calculator
  • EMI Calculator
  • Used Car Loan EMI Calculator
  • Interest Calculator
  • SIP Calculator
  • Credit Score Simulator
  • Flexi Day Wise Interest Calculator
  • Flexi Transaction Calculator
  • Secured Business Loan EMI Calculator
  • Secured Business Loan Eligibility Calculator
  • Lumpsum Calculator
  • Step Up SIP Calculator
  • BMI Calculator
  • IDV Calculator
  • Commercial Loan EMI Calculator
  • Medical Equipment Finance EMI Calculator
  • Term Loan Calculator
  • Equipment Machinery Loan EMI Calculator
  • Doctor Loan EMI Calculator
  • Doctor Loan Eligibility Calculator
  • Chartered Accountant Loan EMI Calculator
  • Simple Interest Calculator
  • Compound Interest Calculator
  • Brokerage Calculator
  • Mutual Fund Calculator
  • Two wheeler Loan EMI Calculator
  • New Car Loan EMI Calculator

Legal

  • Moratorium Policy (Covid-19)
  • Moratorium Policy March 2020
  • Information Security Practices
  • Information Security Measures
  • Citizens Charter
  • Privacy Policy
  • Phishing
  • Disclaimer
  • Forms Centre
  • Fees & Charges
  • Fair Practices Code
  • Interest Rate Policy
  • Disclosures
  • Cautionary Notice
  • Whistle Blower Policy
  • Confidential Feedback
  • Resolution Plan 2.0
  • Terms & Conditions
  • Resolution Plan 2.0 FAQs
  • Ombudsman Scheme
  • SMA/NPA Account Classification
  • Terms of Use
  • Sachet
  • Handover of Property Documents
  • Notices
  • Policy on Fees & Charges
  • BFL - Floating Reference Rates

Reach Us

  • Contact us
  • Raise A Request
  • Frequently Asked Questions
  • Make Online Payment
  • Branch Locator
  • Our Partners
  • Galaxy - Partner portal
  • Bajaj Finserv for Business
  • Call Us

Corporate Office

6th Floor Bajaj Finserv Corporate Office, Off Pune-Ahmednagar Road, Viman Nagar, Pune - 411014

Bajaj Finance Limited Regd. Office

Akurdi, Pune - 411035
Ph No.: 020 7157-6403
Email ID: investor.service@bajajfinserv.in

Corporate Identity Number (CIN)

L65910MH1987PLC042961

IRDAI Corporate Agency (Composite) Regn No.

CA0101
(Valid till 31-Mar-2028)

URN - WEB/BFL/23-24/1/V1

Bajaj Finserv Limited Regd. Office

Bajaj Auto Limited Complex Mumbai - Pune Road,
Pune - 411035 MH (IN)
Ph No.: 020 7157-6064
Email ID: investors@bajajfinserv.in

Corporate Identity Number (CIN)

L65923PN2007PLC130075

Our Companies

  • Bajaj Finserv Ltd.
  • Bajaj Finance Ltd.
  • Bajaj Allianz General Insurance
  • Bajaj Allianz Life Insurance
  • Bajaj Markets
  • Bajaj Housing Finance Ltd.
  • Bajaj Broking
  • Bajaj Finserv Health Ltd.
  • Bajaj Finserv Asset Management Ltd.
Company Name
Download App

© Bajaj Finserv 2007-2025. All rights reserved.